


21

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 89/781,081 10/700,906													
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2004 11/4/03													
				GROUP: 1615															
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
		3	9	6	5	2	5	6											
HS	AA	3	9	6	5	2	5	6	06/22/1976	Leslie	424	22							
	AB	4	2	3	7	4	4	0	12/02/1980	Dudzinski	424	260							
	AC	4	3	6	6	3	1	0	12/28/1982	Leslie	536	56							
	AD	4	4	4	3	4	2	9	04/17/1984	Oshlack, et al.	424	22							
	AE	4	8	2	4	8	3	6	05/09/1989	Elger, et al.	424	419							
	AF	4	8	3	4	9	6	5	05/30/1989	Martani, et al.	424	488							
	AG	4	8	3	4	9	8	4	05/30/1989	Goldie, et al.	424	488							
	AH	4	8	3	4	9	8	5	05/30/1989	Elger, et al.	424	488							
	AI	4	8	4	4	9	0	7	07/04/1989	Elger, et al.	424	465							
HS	AJ	4	8	4	4	9	4	9	07/04/1989	Goldie, et al.	424	480							
FOREIGN PATENT DOCUMENTS																			
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
		0	1	9	3	3	5	5					YES	NO					
HS	AK	0	1	9	3	3	5	5	09/03/1986	Europe (A3)	A61K	31/615							
HS	AL	0	3	1	9	2	4	3	06/07/1989	Europe (A1)	A61K	31/485							
HS	AM	0	3	1	9	2	4	3	11/07/1990	Europe (A2)	A61K	31/485							
HS	AN	0	0	0	1	3	7	7	01/13/2000	WO	A61K	31/00							
HS	AO	9	0	0	4	9	6	5	05/17/1990	WO	A61K	31/485							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)																			
HS	AP	Translation of previously submitted German patent application DE 43 25 465																	
HS	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205																	
HS	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663																	
EXAMINER										/Humera Sheikh/					DATE CONSIDERED				
															01/21/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																			

FORM-PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 <u>10/700,906</u>							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: February 8, 2001 <u>11/04/03</u>		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	BA	4	8	4	4	9	1	0	07/04/1989	Leslie, et al.	424	494	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	BB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9											
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429											
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83											
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 th National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349											
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
	BH	Briscoe, et al., "Methoclocinnamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399											
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551											
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343											
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Thera (1974) Vol. 15; No. 6 pg. 556-564											
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F											
	BM	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May: 51 (5) pg. 713-737											
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8											
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Thera (1984) Vol. 36, No. 5, pg. 704-708											
	BP	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159; pg. 351-360											
HS	BQ	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280											
EXAMINER /Humera Sheikh/									DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,881 10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: February 8, 2001 11/04/03		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	CA	4 8 6 7 9 6 5	09/19/1989	Heafield, et al.	424	461	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	CB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
HS	CG	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11					
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131					
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577					
	CF	Fishman, et al., "Disposition of Naloxone-7,8- ³ H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580					
	CG	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386					
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (I) (2000) pg. 24-30					
	CI	Fudala, et al., "Effects of Burpenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8					
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306					
	CK	Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542					
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41					
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113					
	CN	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197					
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647					
HS	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting <i>Mu</i> Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236					
EXAMINER /Humera Sheikh/				DATE CONSIDERED 01/21/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,081 10/700,906							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: February 8, 2001 11/04/03		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DA	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	DA	4	9	4	0	5	8	7	07/10/1990	Jenkins, et al.	424	480	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES NO	
	DB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39											
	DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744											
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135											
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176											
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257											
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846											
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174											
	DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211											
	DK	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458											
	DL	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209											
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242											
	DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993											
	DO	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383											
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634											
	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages											
HS	DR	Umbricht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190											
EXAMINER /Humera Sheikh/									DATE CONSIDERED 01/21/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,081- <u>10/700,906</u>							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: February 8, 2001 <u>11/04/02</u>		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	EA	4	9	7	0	0	7	5	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	EB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034											
	ED	Wang, et al., "Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600											
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261											
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342											
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoRJ 9409, a Nonpeptidic Opioid μ -Agonists/ δ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605											
	EH	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6											
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148											
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336											
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209											
	EL	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445											
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94											
	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630											
HS	EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385											
EXAMINER /Humera Sheikh/									DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781-081 10/700,906									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2004 11/04/03									
				GROUP: 1615											
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	FA	4	9	6	7	1	3	6	01/22/1991	Kreek, et al.	514	282			
HS	FB	4	9	9	0	3	4	1	02/05/1991	Goldie, et al.	424	484			
HS	FC	5	9	7	1	6	4	6	12/10/1991	Malikowska, et al.	424	497			
HS	FD	5	0	9	1	1	8	9	02/25/1992	Heafield, et al.	424	457			
HS	FE	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488			
HS	FE	5	2	2	6	3	3	1	07/13/1993	Thompson, et al.	73	865.9			
HS	FG	5	2	6	6	3	3	1	11/30/1993	Oshlack, et al.	424	468			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	FH														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
HS	FL	Budd, Keith, "Clinical use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011													
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; Proc. Natl. Acad. Sci (1995) Vol 92, pp. 10540-10544													
	FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105													
	FL	Leeling, et al., "Disposition and metabolism of codorphone in the rat, dog and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp. 649-653													
	FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152													
	FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130													
	FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pp. 420-426													
	FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pp. 29-37													
	FQ	Kanoj, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pp. 355-363													
HS	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pp. 906-909													
EXAMINER /Humera Sheikh/											DATE CONSIDERED 01/21/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/700,906								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001 11/04/03		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	GA	5	2	8	6	4	9	3	02/15/1994	Oshlack, et al.	424	468		
HS	GB	5	3	2	4	3	5	1	06/28/1994	Oshlack, et al.	106	153		
HS	GC	5	3	3	6	6	9	1	08/09/1994	Raffa, et al.	514	629		
HS	GD	5	3	5	6	4	6	7	10/18/1994	Oshlack, et al.	106	153		
HS	GE	5	4	1	1	7	4	5	05/02/1995	Oshlack, et al.	424	456		
HS	GF	5	4	6	0	8	2	6	10/24/1995	Merrill, et al.	424	470		
HS	GG	5	4	7	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	GH	8	7	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
HS	GI	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
HS	GJ	0	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
HS	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1; pg. 29-34												
HS	GL	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151												
HS	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
HS	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
HS	GO	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
HS	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
HS	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577												
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/700,906								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001 11/24/03		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	HA	5	4	2	8	5	7	2	12/26/1995	Sackler, et al.	424	489		
HS	HB	5	5	0	0	2	2	7	03/19/1996	Oshlack, et al.	424	476		
HS	HC	5	5	0	8	0	4	2	04/16/1996	Oshlack, et al.	424	468		
HS	HD	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484		
HS	HE	5	5	4	9	9	1	2	08/27/1996	Oshlack, et al.	424	468		
HS	HF	5	5	5	2	4	2	7	09/03/1996	Gauthier, et al.	514	368		
HS	HG	5	5	9	1	4	5	2	01/07/1997	Miller, et al.	424	468		
HS	HH	5	6	0	1	8	4	5	02/11/1997	Buxton, et al.	424	495		
HS	HI	5	6	2	7	7	2	2	04/22/1997	Knott, et al.	424	494		
HS	HJ	5	6	3	9	4	7	6	06/17/1997	Oshlack, et al.	424	468		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	HK													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
HS	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160												
HS	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607												
HS	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442												
HS	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46												
HS	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101												
HS	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166												
HS	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948												
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,081 10/700,906									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.											
				FILING DATE: February 8, 2001 11/14/03		GROUP: 1615									
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
HS	IA	5	6	5	6	2	9	5	08/12/1997	Oshlack, et al.	424	468			
HS	IB	5	6	7	0	1	7	2	09/23/1997	Buxton, et al.	424	495			
HS	IC	5	6	7	2	3	6	0	09/30/1997	Sackler, et al.	424	490			
HS	ID	5	6	8	1	5	8	5	10/28/1997	Oshlack, et al.	424	494			
HS	IE	5	7	6	3	4	5	2	06/09/1998	Miller, et al.	514	282			
HS	IF	5	7	8	0	4	7	9	07/14/1998	Kim	514	282			
HS	IG	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498			
HS	IH	5	8	3	4	4	7	2	11/10/1998	Mioduszewski	514	282			
HS	II	5	8	4	3	4	8	0	12/01/1998	Miller, et al.	424	484			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
	IJ														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
HS	IK	Pärwartikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354													
HS	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508													
HS	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490													
HS	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823													
HS	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34													
HS	IP	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149													
HS	IQ	Wikler, et al., "N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20													
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 097781,081 10/700,906							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2001 10/04/03							
				GROUP: 1615									
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	ID	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	JA	5	8	4	9	2	4	0	12/15/1998	Miller, et al.	264	460	
HS	JB	5	8	6	9	0	9	7	02/09/1999	Wong, et al.	424	473	
HS	JC	5	8	7	5	7	6	5	03/09/1999	Heafield, et al.	424	464	
HS	JD	5	8	9	1	4	7	1	04/06/1999	Miller, et al.	424	468	
HS	JE	5	9	0	8	8	4	8	06/01/1999	Miller, et al.	514	282	
HS	JF	5	8	5	8	4	5	2	09/28/1999	Oshlack, et al.	424	457	
HS	JG	5	9	5	8	4	5	9	09/28/1999	Chasin, et al.	424	490	
HS	JH	5	9	6	5	1	6	1	10/12/1999	Oshlack, et al.	424	457	
HS	JI	5	9	6	5	1	6	3	10/12/1999	Miller, et al.	424	468	
HS	JJ	5	9	6	8	5	5	1	10/19/1999	Oshlack, et al.	424	456	
FOREIGN PATENT DOCUMENTS													
ID	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
JK													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	JL	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110											
HS	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58											
HS	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
HS	JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529											
HS	JP	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258											
HS	JO	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526											
HS	JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217											
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 097781,081 <u>10/700,906</u>	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2001 <u>11/04/03</u>	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	KA	6 0 2 4 9 8 2	02/15/2000	Oshlack, et al.	424	476	
	KB	6 0 6 8 8 5 5	05/30/2000	Leslie, et al.	424	468	
	KC	6 0 7 7 5 3 2	06/20/2000	Malkowska, et al.	424	457	
	KD	6 0 2 7 5 3 3	06/20/2000	Oshlack, et al.	424	461	
	KE	6 1 0 3 2 5 0	08/15/2000	Simon	424	449	
	KF	6 1 0 3 2 6 1	08/15/2001	Chasin, et al.	424	459	
	KG	6 1 4 3 3 7 2	11/07/2000	Sackler, et al.	424	459	
	KH	6 1 4 3 3 2 8	11/07/2000	Heafield, et al.	424	489	
	KJ	6 1 6 2 4 6 7	12/19/2000	Miller, et al.	424	468	
	KJ	6 2 1 0 2 1 4	04/03/2001	Oshlack, et al.	424	476	
	KK	6 2 5 4 8 8 7	07/03/2001	Miller, et al.	424	468	
↓	KL	6 2 6 1 5 9 9	07/17/2001	Oshlack, et al.	424	457	
HS	KM	6 2 9 4 1 9 5	09/25/2001	Oshlack, et al.	424	457	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
HS	KN	0 1 3 7 7 8 5	05/31/2001	WO (A2)	A61K		
HS	KO	0 1 5 2 8 5 1	07/26/2001	WO (A1)	A61K	31/485	
HS	KP	0 1 8 5 2 5 7	11/15/2001	WO (A2)	A61P		
HS	KQ	0 1 9 3 8 5 2	12/13/2001	WO (A2)	A61K	31/00	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
HS	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82					
HS	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim.-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022					
EXAMINER: /Humera Sheikh/			DATE CONSIDERED 01/21/2007				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/700,906									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.											
				FILING DATE: February 8, 2001 11/04/03		GROUP: 1615									
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
HS	LA	6	3	0	6	4	3	8	10/23/2001	Oshlack, et al.	424	468			
HS	LB	6	3	2	6	0	2	7	12/04/2001	Miller, et al.	424	468			
HS	LC	6	3	3	5	0	3	3	01/01/2002	Oshlack, et al.	424	457			
HS	LD	6	3	7	5	9	5	7	04/23/2002	Kaiko, et al.	424	400			
HS	LE	6	3	8	7	4	0	4	05/14/2002	Oshlack, et al.	424	480			
HS	LF	6	3	9	9	0	9	6	06/04/2002	Miller, et al.	424	464			
HS	LG	6	4	7	5	4	9	4	11/05/2002	Kaiko, et al.	424	400			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
	LH														
	LI														
	LL														
	LK														
	LL														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	LM														
	LN														
	LO														
	LP														
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/701,081 10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Curtis Wright et al.			
				FILING DATE: February 8, 2001 11/04/03		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<div style="font-size: 2em;">V</div>	AA	5 9 9 8 4 3 4	12/99	Mitch et al.	514	210.16	
	AB	5 9 7 2 9 5 4	10/99	Foss	514	282	
	AC	5 9 8 8 5 4 7	10/99	Reeder et al.	424	449	
	AD	5 9 4 2 2 4 1	8/99	Chasin et al.	424	426	
	AE	5 8 8 0 1 3 2	3/99	Hill	514	282	
	AF	5 8 6 6 1 6 4	2/99	Kuczynski et al.	424	472	
	AG	5 8 6 0 9 5 0	1/99	Demopoulos et al.	604	49	
	AH	5 8 5 8 0 1 7	1/99	Demopoulos et al.	604	890.1	
	AI	5 7 6 7 1 2 5	6/98	Crain et al.	514	282	
	AJ	5 6 3 3 2 5 9	5/97	Qin et al.	514	282	
	AK	5 6 2 4 5 3 2	4/97	Qin et al.	514	282	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
HS	AI	19 6 5 1 5 5 1	6/98	DE	A61K	31/485	YES NO
HS	AM	29 7 1 9 7 0 4	2/97	DE	A61K	31/485	
HS	AN	4 3 7 5 4 6 5	2/95	DE	A61K	31/485	X
HS	AO	2 2 2 2 0 3 5	11/72	DE	A61K	27/00	
HS	AP	0 9 1 3 1 5 2	6/99	EP	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
HS	AQ	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.					
HS	AR	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.					
HS	AS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.					
EXAMINER <div style="text-align: center;">/Humera Sheikh/</div>				DATE CONSIDERED 01/21/2007			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/761,061 10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.			
						FILING DATE: February 8, 2001 4/04/03		GROUP: 1615	

U.S. PATENT DOCUMENTS														
*EXAMINE R INITIAL	DOCUMENT NUMBER	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	BA	5	6	1	6	6	0	1	4/97	Khanna et al.	514	399		
	BB	5	5	0	5	3	4	8	12/96	Crain et al.	514	12		
	BG	5	5	8	0	8	7	6	12/96	Crain et al.	514	282		
	BD	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35		
	BE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343		
	BF	5	5	5	8	8	3	8	9/96	Mayer et al.	514	25		
	BG	5	5	3	4	4	9	7	7/96	Aston et al.	514	608		
	BH	5	5	1	4	8	9	0	5/96	Weber et al.	514	249		
	BI	5	5	1	2	5	7	8	4/96	Crain et al.	514	282		
	BJ	5	5	0	7	0	5	9	3/96	Mayer et al.	514	289		
HS	BK	5	4	8	6	3	0	2	1/96	Kitchell et al.	424	426		

FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER	DOCUMENT NUMBER	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO												
HS	BI	0	6	4	7	4	4	8	4/95	EP	A61K	31/485			
HS	BM	0	3	5	2	3	0	1	1/90	EP	A61K	31/485			
HS	BN	9	2	0	5	2	8	2	12/86	EP	A61K	9/22			
HS	BO	9	9	3	2	1	2	0	7/99	WO	A61K	31/485			
HS	BP	9	0	3	5	6	7	9	8/98	WO	A61K	31/485			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
HS	BQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.
HS	BR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.

EXAMINER /Humera Sheikh/	DATE CONSIDERED 01/21/2007
---------------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 <u>10/700,806</u>	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Curtis Wright et al.			
				FILING DATE: February 8, 2001 <u>11/04/03</u>		GROUP: 1615	

U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL	CA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	CA	5	4	2	3	9	4	3	12/95	Crain et al.	514	12	
	CB	5	4	9	7	2	0	8	10/95	Portoghese et al.	546	35	
	CC	5	4	2	6	1	1	2	6/95	Zagon et al.	514	282	
	CD	5	3	7	6	6	6	2	12/94	Ockert	514	282	
	CE	5	3	5	6	9	0	0	10/94	Bihari et al.	514	282	
	CF	6	3	5	2	6	8	3	10/94	Mayer et al.	514	289	
	CG	5	3	5	2	6	8	0	10/94	Portoghese et al.	514	279	
	CH	5	3	2	1	6	1	2	6/94	Mayer et al.	514	25	
	CI	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282	
	CJ	5	3	1	6	7	5	9	5/94	Rose et al.	424	10	
HS	CK	6	2	7	3	7	6	6	12/93	Oshlack et al.	424	486	

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO											
HS	CI	9	7	3	3	5	6	6	9/97	WO	A61K	9/20		
HS	CM	9	6	0	2	2	5	1	2/96	WO	A61K	31/485		
HS	CN	9	5	0	3	8	0	4	2/95	WO	A61K	31/485		
HS	CO	3	4	6	6	4	2	6	3/94	WO	A61K	31/46		
HS	CP	6	3	0	3	1	9	7	9/83	WO	A61K	9/22		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
HS	CQ	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.
HS	CR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).

EXAMINER /Humera Sheikh/	DATE CONSIDERED 01/21/2007
------------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.			
						FILING DATE: February 8, 2004 11/04/03		GROUP: 1615	
U.S. PATENT DOCUMENTS									
*EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
↓	DA	5 2 5 6 6 6 9	10/93	Askanazi et al.	514	282			
	DB	5 2 3 6 7 1 4	8/93	Lee et al.	424	449			
	DC	5 2 2 5 4 4 0	7/93	London et al.	514	535			
	DD	5 1 4 9 5 3 8	9/92	Granger et al.	424	449			
	DE	5 1 0 2 8 8 7	4/92	Goldberg	514	282			
	DF	5 0 9 6 7 1 5	3/92	Sinclair	424	449			
	DG	5 0 8 6 0 5 8	2/92	Sinclair et al.	514	282			
	DH	5 9 7 5 3 4 1	12/91	Mendelson et al.	514	282			
	DI	4 9 3 5 4 2 8	6/90	Lewis	514	282			
	DJ	4 8 8 9 8 6 0	12/89	Rzeszotarski et al.	514	282			
HS	DK	4 8 8 2 3 3 5	11/89	Sinclair	514	282			
FOREIGN PATENT DOCUMENTS									
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
						YES	NO		
	DL								
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
HS	DM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.							
HS	DN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.							
HS	DO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.							
HS	DP	Physician's Desk Reference 48 th Ed. (1994) Montvale, NJ, 2120-2121.							
HS	DQ	Foss et al., J. Clin Pharmacol (1993), 33:747-751.							
EXAMINER /Humera Sheikh/				DATE CONSIDERED 01/21/2007					
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 69781-081 10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.			
						FILING DATE: February 8, 2004 11/04/03		GROUP: 1615	

U.S. PATENT DOCUMENTS														
*EXAMINE R INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	EA	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10		
	EB	4	8	6	1	7	8	1	8/89	Goldberg	514	282		
	EC	4	8	6	1	5	9	8	8/89	Oshlack et al.				
	ED	4	6	6	6	5	5	8	2/89	Wuest et al.	514	381		
	EE	4	8	0	6	5	4	3	2/89	Choi	514	464		
	EF	4	8	0	6	3	4	1	2/89	Chien et al.	424	448		
	EG	4	8	0	3	2	0	8	2/89	Pasternak	514	282		
	EH	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282		
	EI	4	7	6	9	3	7	7	9/88	Kreek et al.	514	282		
	EJ	4	7	6	0	0	6	9	7/88	Rzeszotarski et al.	514	282		
HS	EK	4	7	3	0	0	4	8	3/88	Portoghese et al.	546	45		

FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	EL														

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
HS	EM	Holmes et al., Anesth. Analg. (1993), 77:1166-73.
HS	EN	Miaskowski et al., Brain Research (1992), 596:41-45.
HS	EO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.
HS	EP	Cappel et al., Pharma. Bioch. & Behav. (1989), 34:425-427.
HS	EQ	Vaccarino et al., Pain (1989), 36:103-109.
HS	ER	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.

EXAMINER /Humera Sheikhs/	DATE CONSIDERED 01/21/2007
------------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/700,906													
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.															
						FILING DATE: February 8, 2001 11/04/03		GROUP: 1615													
U.S. PATENT DOCUMENTS																					
*EXAMINE R INITIAL	FA	FB	FC	FD	FE	FF	FG	FH	FI	FJ	FK	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
HS												4 7 1 9 2 1 5	1/88	Goldberg	514	282					
												4 6 8 1 4 9 2	4/87	Lewis et al.	514	282					
												4 6 0 8 3 2 6	8/86	Pasternak	514	282					
												4 5 8 2 8 3 5	4/86	Lewis et al.	514	282					
												4 5 7 3 9 9 5	3/86	Chen et al.	604	896					
												4 4 6 4 3 7 8	8/84	Hussain et al.	424	260					
												4 4 5 7 9 3 3	7/84	Gordon et al.	424	260					
												4 4 6 1 4 7 9	5/84	Ganti	424	260					
												4 4 0 1 6 2 2	8/83	Portoghese et al.	424	260					
↓												4 1 7 6 1 8 6	11/79	Goldberg	424	260					
HS												3 9 6 6 9 4 0	6/76	Pachter et al.	424	260					
FOREIGN PATENT DOCUMENTS																					
				DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
																YES	NO				
		FI																			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)																					
HS	FM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.																			
HS	FN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.																			
	FO																				
	FP																				
	FQ																				
	FR																				
EXAMINER										/Humera Sheikh/								DATE CONSIDERED		01/21/2007	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered: Include copy of this form with next communication to applicant.																					

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 16/700,906							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.									
						FILING DATE: February 8, 2001 11/04/03		GROUP: 1615							
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL	CLASS	DOCUMENT-NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	GA	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260			
HS	GB	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260			
HS	GC	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260			
HS	GD	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260			
HS	GE	3	3	3	7	9	5	0	7/67	Blumberg et al.	260	285			
HS	GF	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65			
	GG														
	GH														
	GI														
	GJ														
	GK														
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	GL														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	GM														
	GN														
	GO														
	GP														
	GQ														
	GR														
	GS														
EXAMINER /Humera Sheikh/											DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 8, 2001

11/04/03

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	AA	6	2	2	8	8	6	3	05/08/01	Palermo et al.	514	282	
HS	AB	6	2	7	7	3	8	4	08/21/01	Kaiko et al.	424	400	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	AC	WO	98	2	5	6	1	3	06/18/98	EPO	A61K	31/485	Abstract	
HS	AD	WO	00	3	8	6	4	9	07/06/00	EPO	A61K	9/00	Abstract	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HS	AE	Press Release entitled "International Patent Application To Be Published on Abuse-Resistant Pain Reliever Being Developed by Purdue Pharma" August 8, 2001.											
HS	AF	Paronis, et al., Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats, J Pharm. Exper. Ther. 1991 259(2) pg 582-589											
HS	AG	Yoburn, et al., Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Selectivity, Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539											
HS	AH	Crain, et al., Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia, Brain Res. 2001 888 pg 75-82											
HS	AI	Zhang, et al., Down-Regulation of μ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy, Neuroscience 1998 82, pg 223-240											
HS	AJ	Abdulla, et al., Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J. Neuro Sci 1998 18, pg 9685-9694											
HS	AK	Di Giannuario, et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett. 1999 272, pg 183-186											
HS	AL	Ciccocioppo, et al., Effect of nociceptin/orphanin FQ on the rewarding properties of morphine, Eur. J. Pharmacol. 2000 404, pg 153-159											
	AM												
	AN												

EXAMINER

/Humera Sheikh/ 01/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,081 107,700,906	
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Curtis WRIGHT, et al.			
(Use several sheets if necessary)				FILING DATE: February 8, 2001 11/04/03		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
HS	AA	Benfey, Function of Myocardial α -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112					
HS	AB	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577					
HS	AC	Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240					
HS	AD	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ , δ or κ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288					
HS	AE	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38					
HS	AF	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79					
HS	AG	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131					
EXAMINER /Humera Sheikh/				DATE CONSIDERED 01/21/2007			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON5SERIAL NO.:
10/700,906

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
~~To be assigned~~ 16/5

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	AA	4	5	8	7	1	1	8	05/06/1986	Hsiao	424	459	
	AB												
	AC												
	AD												
	AE												
	AF												
	AG												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	AH	04	0	5	2	3	4	6	06/24/04	WO (A1)	A61K	9/62		
HS	AI	0	5	4	8	4	4	8	09/06/2000	EP (B1)	A61K	9/50	abstract	
	AJ													
	AK													
	AL													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER /Humera Sheikh/

DATE CONSIDERED 01/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON5SERIAL NO.:
10/700,906

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
HS	AH	1 3 9 0 7 7 2	04/16/1975	GB	A61K31	485		
	AI							
	AJ							
	AK							
	AL							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER

/Humera Sheikh/

DATE CONSIDERED

01/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.